EFFECT OF SIMVASTATIN IN SERUM INTERLEUKIN-6 LEVEL IN PATIENTS WITH ACUTE ISCHEMIC STROKE

Maria Lettisia Meo¹, Abdullah Machin², Didik Hasmono³
¹Master Program of Clinical Pharmacy, Faculty of Pharmacy, ²Department of Neurology, Soetomo Teaching Hospital Surabaya, ³Department of Clinical Pharmacy, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia

ABSTRACT

Acute ischemic stroke is the leading cause of death and causing permanent disability in adults worldwide. In acute ischemic stroke, IL-6 levels positively correlated to more severe neurological deficits, more extensive brain damage and worse prognoses. The use of statin was associated with milder initial stroke severity, better functional outcome and lower mortality. This clinically randomized controlled trial study was aimed to analyze the serum levels of IL-6 in acute ischemic stroke patients who were treated with Simvastatin 20 mg compare to placebo. Samples were taken using consecutive sampling method from hospitalized acute ischemic stroke patients in Neurology Department of Dr. Soetomo Teaching Hospital Surabaya and Airlangga University Hospital Surabaya from August to November 2017. Total of 44 patients met the inclusion criteria, consisting of 22 patients in treatment group and 22 patients in control group. There were no significant difference in the characteristic of the patients in both groups (p>0.05). Averages of serum IL-6 in the control and the treatment group are 38.594±24.313 and 17.760±25.253 (p=0.438) while averages of serum IL-6 post in the control group and the treatment are 46.586±103.484 and 15.275±7.183 (p=0.589). There were no significant level escalation in pre and post of control group (p=0.205) and also no significant level reduction in pre and post of treatment group (p=0.411), while the average difference in the control group (-7.992 ± 78.912 pg/ml) and in the treatment group (2.485 ± 23.738 pg/ml).

Keywords: Acute ischemic stroke; IL-6; Simvastatin

INTRODUCTION

Ischemic stroke is a general stroke happened rather than hemorrhagic stroke. It is well marked by suddenly loss of blood circulation to brain in result of thrombotic occlusion or cerebral artery occlusion. In USA, stroke is in the fourth from five leading cause of death, besides heart disease, cancer, chronic lower respiratory disease...
and injury. It is also become the second leading cause of death worldwide after heart disease, which is 11.13% from total death in the world (Neena, 2015; Mozaffarian, et al., 2016). National Basic Health Research (Riset Kesehatan Dasar (Risksdas) Nasional) of 2013 shows there is growth of stroke prevalence in Indonesia which 8.3 per mil in 2007 to 12.1 per mil in 2013 (Balitbangkes, 2013).

Inflammation process has a main role in the whole ischemic stroke pathogenesis. The inflammation occurs in hours after the ischemic onset, marked with molecule adhesion in blood vessel endhotel and leukocytes in the circulation to brain parenchyma. Leukocytes are out of the circulation passing through the endhotel and penetrating brain parenchyma tissue which leading inflammation reaction. Majority part of inflammation is determined by population of microglia cell. This inflammation cause secondary damage of neuron cell (Deb, Sharma & K., 2010; Misbach, et al., 2011).

Decreased blood flow to the brain in ischemic stroke is a direct reaction to the glucose and oxygen deficiency, will lead to loss of ion balance, calcium deregulations, acidosis, and excitotoxicity which become a manifests to damage cell or death cell. This event causes passive release of Danger Associated Molecular Pattern Molecules (DAMPs), which binds and activates Pattern-Recognition Receptors (PRR) and triggers activation of the innate immune system and initiates inflammation (Gesueute, et al., 2014). High-mobility Group Protein B1 (HMGB-1) is a typical DAMP molecule which initiates inflammation through Toll-Like Receptors (TLRs) such as TLR-2 and TLR-4 (Zhao, et al., 2015).

TLR sticky wakes the signal and triggers transcription factor like Nuclear Factor Kappa B (NF-kB) which promote the expressions of various pro-inflammation cytokine like Tumor Necrosis Factor-Alpha (TNF-α), Interleukin-6 (IL-6) and Interleukin-1β (IL-1β) (Abbas, et al., 2016). However, the increase of this pro-inflammation cytokine is a disadvantage since it leads neuron death in instance (D014, et al., 2014). IL-6 is a pro-inflammatory cytokine produced by various cells including monocytes, macrophages, fibroblasts, endothelial cells, keratinocytes, mast cells, T lymphocytes, and also by microglia and astrocytes. IL-6 is a key mediator of acute phase reaction. IL-6 level of ischemic stroke patients arise in 24 hours and reach the peak in 2-3 days after the stroke (Tarkowski, et al., 1995). On the other side, there is a stating that IL-6 level arise in first week after the ischemic stroke. However, some studies show IL-6 level are peaking in 10 hours in the serum meanwhile other studies show IL-6 level are peaking on between third to the seventh day after the stroke. Though, the peaking time of IL-6 apparently depends on stroke severity (Waje, et al., 2005; D014, et al., 2014). (Wajo5-Andreasen, et al., 2005)

Increased level of IL-6 in the first week of ischemic stroke is correlated significantly with the volume infarction on the fifth to the seventh day and clinical result at 3 months. Secondary analysis also shows a strong association between peak plasma of IL-6 and stroke severity, clinical outcomes or mortality at 12 months (Smith, et al., 2004). In addition, increased level of IL-6 on the first and fifth days relates to mortality, functional disability, and performance status (in the third month and first year) in patients with acute ischemic (Syaafi, et al., 2014), as well as a strong predictor of the infarct volumes and neurological deficits. Higher level of IL-6 has a significant effect on poor outcome and mortality in 6 months after the stroke (Whiteley, 2009).

Endothelial dysfunction, thrombogenesis, inflammation, oxidative stress damage and angiogenesis play an important role in ischemic pathogenesis of the brain and are targets for the prevention and treatment of ischemic stroke. Statins are inhibitors reductase 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG-CoA) that can improve endothelial function, modulate thrombogenesis, reduce inflammatory damage and oxidative stress, and facilitate angiogenesis far beyond lowering cholesterol level (Zhao, Zhang, Dong, & Wen, 2014).

The anti-inflammatory effect of statins through the mevalonate pathway inhibits the conversion of HMG-CoA into mevalonate which is a pathway in cholesterol synthesis (Bonaventura & Liberale, 2016). The resistance of isoprenoid production causes the transduction of Rho signals to be inhibited. This leads to activation of Peroxisome Proliferator-Activated Receptor-α (PPAR-α) and Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) and inhibits activation of transcription factors of inflammation Activating Protein-1 (AP-1) and NF-kB, thus, lowering the expression of pro-inflammatory cytokines (IL-6, IL-1, TNF-α) (Rasmussen, et al., 2001; Jingru Zhao, et al., 2014).

In clinical tests with simvastatin in acute ischemic stroke (AIS), Montaner et al. (2008) shows more complete cases of functional recovery after 3 months of treatment with simvastatin 40 mg/day during the first 1 week and continued 20 mg/day for up to 90 days, compared with the group not given simvastatin (p<0.05). Significant increases were observed on day 3 of treatment, but became vulnerable to infection risk. In a review of meta-analysis, Statin use is associated with decreased inflammatory biomarkers, i.e. CRP and
cytokines (IL-1, IL-6, IL-12, TNF-α, IFN-γ) (Zhao, Zhang, et al., 2014).

Until now, in SMF Science of Neurology RSUD Dr. Soetomo Surabaya, the use of simvastatin is still limited as a lipid lowering agent in addition to three other types of statins such as pravastatin, atorvastatin and rosuvastatin. But in practice, it still refers to the established provisions in the national formulary, such as the use of atorvastatin and rosuvastatin if by consuming simvastatin the patient does not achieve the LDL reduction target. This is in accordance with the restrictions contained in the National Health Insurance (JKN) system for the services of JKN patients (Kemenkes, 2015).

Besides using in patients with hyperlipidemia, simvastatin also has a pleiotropic effect with its anti-inflammatory effects as well as lipid-lowering agents. Hence, research on other biomarkers to measure the effectiveness of simvastatin administration in ischemic stroke conditions is needed. Based on this, this study was conducted to analyze the effects of anti-inflammatory simvastatin in patients with acute ischemic stroke using interleukin-6 (IL-6) pro-inflammatory cytokine biomarkers.

**MATERIALS AND METHODS**

This study is part of the Influence of Simvastatin on Inflammatory Marker in Acute Ischemic Stroke (ISIM Study) study which is a randomized controlled trial clinical test of patients with acute ischemic stroke who had a stroke occurred ≤ 24 hours before hospitalized in hospital, male and female patients ≥ 18 years and signed informed consent. Samples were taken by consecutive sampling that is acute ischemic stroke patients who hospitalized in IRNA Medical SMF Science of Neurology, Dr. Soetomo Hospital and Universitas Airlangga Hospital in Surabaya during the period August to November 2017. Prior to the research, researchers have received the approval of ethical acceptance by the Committee of Medical Research Ethics RSUD Dr. Soetomo Surabaya based on Ethical Clearance Certificate No. 447/Panke.KKE/VII/2017 and the approval of ethical acceptance by the Ethics and Law Committee of Airlangga University Hospital based on the Ethical Passing Certificate No. 127/KEH/2017.

This study observed patient’s characteristics, include gender, age, smoking history, history of disease including hypertension, diabetes mellitus, heart, stroke and therapy gained during the study (ASA, CDP cholin, metamizole, vitamin B1, B6, B12) as shown in Table 1.

Table 1 shows that the average age of acute ischemic stroke patients in both groups was 61.4 years for the placebo (control) group and 58.7 years for the treatment group (simvastatin). After the statistical tests, there were no significant difference between the two groups (p=0.452). In addition to age, the sexes in both groups did not differ significantly (p=0.215).

Some of the risk factors were found in patients includes smoking habits and the history of diseases such as hypertension, diabetes, heart and stroke. From the table above, the most common risk factors were found in both groups of patients is hypertension with percentage in control group patients 95.5% while in the treatment group 77.3%. After comparison between the two groups, there was no significant difference (p=0.082).

Analysis of serum level was using Quanticine ELISA Human IL-6 Immunoassay Datasheet (R & D System, Minneapolis, USA). The data obtained were serum IL-6 levels in pg/mL.

The difference between serum IL-6 levels pre- and post-simvastatin of 20 mg was analyzed by paired t-test for normal distributed data and the Wilcoxon signed ranks test for abnormal distributed data. Meanwhile, to compare serum IL-6 levels in both groups (intervention group and control group) was used independent t-test for normal distributed data and Mann-Whitney test for abnormal distributed data. Data processing used Statistical Package for the Social Sciences (SPSS) program.

**RESULTS**

A study on the effect of simvastatin given on serum IL-6 levels in acute ischemic stroke patients have been done in the overstaying installment room (IRNA) of SMF Medical Science of Neurology RSUD Dr. Soetomo and Hospital Airlangga University during the period August - November 2017. Prior to the research, researchers have received the approval of ethical acceptance by the Committee of Medical Research Ethics RSUD Dr. Soetomo and Hospital Airlangga University during the period August to November 2017. Prior to the research, researchers have received the approval of ethical acceptance by the Committee of Medical Research Ethics RSUD Dr. Soetomo Surabaya based on Ethical Clearance Certificate No. 447/Panke.KKE/VII/2017 and the approval of ethical acceptance by the Ethics and Law Committee of Airlangga University Hospital based on the Ethical Passing Certificate No. 127/KEH/2017.

Table 1 shows the average age of acute ischemic stroke patients in both groups was 61.4 years for the placebo (control) group and 58.7 years for the treatment group (simvastatin). After the statistical tests, there were no significant difference between the two groups (p=0.452). In addition to age, the sexes in both groups did not differ significantly (p=0.215).

Some of the risk factors were found in patients includes smoking habits and the history of diseases such as hypertension, diabetes, heart and stroke. From the table above, the most common risk factors were found in both groups of patients is hypertension with percentage in control group patients 95.5% while in the treatment group 77.3%. After comparison between the two groups, there was no significant difference (p=0.082).
Table 1. Patients’ characteristics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Placebo (n=22)</th>
<th>Simvastatin (n=22)</th>
<th>Total (n=44)</th>
<th>p Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age – average (years)</td>
<td>61.4</td>
<td>58.7</td>
<td>60</td>
<td>0.452</td>
</tr>
<tr>
<td>Gender – amount (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>16 (72.7)</td>
<td>12 (54.5)</td>
<td>28 (63.6)</td>
<td>0.215</td>
</tr>
<tr>
<td>Female</td>
<td>6 (27.3)</td>
<td>10 (45.5)</td>
<td>16 (36.4)</td>
<td></td>
</tr>
<tr>
<td>Smoking history – amount (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>21 (95.5)</td>
<td>17 (77.3)</td>
<td>38 (86.4)</td>
<td>0.082</td>
</tr>
<tr>
<td>Diabetes</td>
<td>5 (22.7)</td>
<td>6 (27.3)</td>
<td>11 (25.0)</td>
<td>0.731</td>
</tr>
<tr>
<td>Heart disease</td>
<td>3 (13.6)</td>
<td>3 (13.6)</td>
<td>6 (13.6)</td>
<td>1.000</td>
</tr>
<tr>
<td>Stroke</td>
<td>6 (27.3)</td>
<td>7 (31.8)</td>
<td>13 (29.5)</td>
<td>0.744</td>
</tr>
<tr>
<td>Disease history – amount (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>21 (95.5)</td>
<td>17 (77.3)</td>
<td>38 (86.4)</td>
<td>0.082</td>
</tr>
<tr>
<td>Diabetes</td>
<td>5 (22.7)</td>
<td>6 (27.3)</td>
<td>11 (25.0)</td>
<td>0.731</td>
</tr>
<tr>
<td>Heart disease</td>
<td>3 (13.6)</td>
<td>3 (13.6)</td>
<td>6 (13.6)</td>
<td>1.000</td>
</tr>
<tr>
<td>Stroke</td>
<td>6 (27.3)</td>
<td>7 (31.8)</td>
<td>13 (29.5)</td>
<td>0.744</td>
</tr>
<tr>
<td>Therapy – amount (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASA</td>
<td>19 (86.4)</td>
<td>20 (90.9)</td>
<td>39 (88.6)</td>
<td>0.639</td>
</tr>
<tr>
<td>CDP Cholin</td>
<td>15 (68.2)</td>
<td>13 (59.1)</td>
<td>28 (63.6)</td>
<td>0.536</td>
</tr>
<tr>
<td>Metamizole</td>
<td>4 (18.2)</td>
<td>2 (9.1)</td>
<td>6 (13.6)</td>
<td>0.385</td>
</tr>
<tr>
<td>Vit B</td>
<td>4 (18.2)</td>
<td>6 (27.3)</td>
<td>10 (27.7)</td>
<td>0.477</td>
</tr>
</tbody>
</table>

Table 2. Statistical analysis of serum IL-6 difference in the control group and treatment group

<table>
<thead>
<tr>
<th></th>
<th>Control (n=22)</th>
<th>Treatment (n=22)</th>
<th>Significancy (p)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average of Serum IL-6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levels before Intervention ± SD (pg/ml)</td>
<td>38.594 ± 74.313</td>
<td>17.760 ± 25.253</td>
<td>0.438</td>
</tr>
<tr>
<td>Average of Serum IL-6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levels after Intervention ± SD (pg/ml)</td>
<td>46.586 ± 103.484</td>
<td>15.275 ± 17.183</td>
<td>0.589</td>
</tr>
<tr>
<td>Average of difference Serum IL-6 ± SD (pg/ml)</td>
<td>-7.992 ± 78.912</td>
<td>2.485 ± 23.738</td>
<td>0.907</td>
</tr>
</tbody>
</table>

Table 3. Statistical analysis of serum IL-6 levels changes in the control group and treatment group before and after intervention

<table>
<thead>
<tr>
<th></th>
<th>Average of Serum IL-6 Levels before Intervention ± SD (pg/ml) (n=44)</th>
<th>Average of Serum IL-6 Levels after Intervention ± SD (pg/ml) (n=44)</th>
<th>Significancy (p)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control Group</td>
<td>38.594 ± 74.313</td>
<td>46.586 ± 103.484</td>
<td>0.205</td>
</tr>
<tr>
<td>Treatment Group</td>
<td>17.760 ± 25.253</td>
<td>15.275 ± 17.183</td>
<td>0.411</td>
</tr>
</tbody>
</table>

For the other risk factors, there were no significant differences in the two groups of patients in the history of diabetes (p=0.731), history of heart disease (p=1.000), previous stroke (p=0.744), smoking habit (p=0.477). During hospitalization, patients also received other therapies such as ASA (acetyl salicylic acid), CDP Cholin, metamizole and also vitamin B1, B6 and B12. These therapies may affect pro-inflammatory markers levels so they can create bias. However, after statistically comparing, there was no significant difference between the two groups.

Blood sampling for each patient in both control and treatment groups to measure the serum Interleukin 6 levels was performed twice: on the first day of hospitalization (before placebo/simvastatin) and on the fifth day of hospitalization (2 hours after simvastatin/placebo).

The research brings out that the range of serum IL-6 levels in the control group before the intervention (pre) is 2.557 - 260.450 pg/ml and after intervention (post) is 0 - 437,950 pg/ml. Serum IL-6 levels are increased in 12 patients (54.54%) of the control group after placebo for 5 days. However, serum IL-6 levels are decreased in 9 patients (40.90%) and 1 patient (4.54%) with no change in serum IL-6 levels after placebo for 5 days. In the treatment group, range of serum IL-6 levels before the intervention (pre) is 0 - 115,336 pg/ml, and after intervention (post) is 0 - 53,937 pg/ml. There are 8
patients (36.36%) with decreased serum of IL-6 levels and 12 patients (54.54%) who have increased and 2 patients (9.09%) with no change of serum of IL-6 level after consuming simvastatin for 5 days. The statistical analysis of serum IL-6 levels difference in the control and treatment groups as well as changes in serum IL-6 levels before and after intervention can be seen in Tables 2 and 3.

Table 2 shows that the average serum IL-6 levels before the intervention in the control group is in the range 38.594 ± 74.313 pg/ml, it is higher compared with the treatment group with a range of 17.760 ± 25.253 pg/ml. However, after the Mann-Whitney test, it is found that the difference is not statistically significant with p>0.05 (p=0.438). After intervention, the average serum IL-6 levels in the treatment group is in the range 15.275 ± 17.183 pg/ml, it is lower than the control group with range 46.586 ± 103.484 pg/ml. After the Mann-Whitney test it is found that the difference is not statistically significant with p>0.05 (p=0.589).

When compared between before and after intervention in the same group (Table 3) it is found that the average serum IL-6 levels in control group increased from the rate of 38.594 ± 74.313 pg/ml to 46.586 ± 103.484 pg/ml, but statistically it does not show the meaningful difference (p=0.205). While in the treatment group, it decreased from the average rate of 17.760 ± 25.253 pg/ml to 15.275 ± 17.183 pg/ml, but this decrease does not show meaningful significance (p=0.411). In the average value of serum IL-6 levels of the control group, negative (-) result is gained, this indicates that the serum IL-6 levels before the intervention (pre) in control group patients have increased, while in the treatment group obtained positive value, this indicates that serum IL-6 levels before the intervention (pre) decrease.

**DISCUSSION**

The aim of this study is to analyze the effect of simvastatin consumption toward changes in IL-6 levels as one of the biomarkers in the inflammatory process that occurs in acute ischemic stroke condition. The study was conducted in IRNA Medical SMF Science of Neurology, Dr. Soetomo Hospital and Universitas Airlangga Hospital Surabaya during the period of August to November 2017. Up to the end of the study, there were 44 patients consisting of 22 control group patients and 22 treatment group patients. The research data are processed based on characteristc data and serum of IL-6 levels of acute ischemic stroke patients from each study group. Data are presented in tables and figures and statistical analyzes are performed using the Mann-Whitney test to determine the ratio of serum IL-6 levels between the two groups (control and treatment) and the Wilcoxon test to determine differences between pre- and post- levels in each group. Before performing Mann-Whitney Test and Wilcoxon test, Kolmogorov-Smirnoff Normalities and Saphiro-Wilk Normalities were used and the result were not normally distributed (p<0.05).

Patient’s demographic data covering gender, age, smoking history, and history of hypertension, diabetes, heart disease, and stroke, and history of therapy are shown in Table 1. It appears that male patients (63.6%) accounted more than female (36.4%) and the average age is 60 years. This is consistent with the results of the study suggesting that male are 1.25 times more likely to have a stroke than female (Samai & Martin-Schild, 2015). The prevalence of ischemic stroke remains stable in individuals aged 18 to 44 and 45 to 64 years but has a tendency to decline at age ≥ 65 years (Benjamin, et al., 2017). Other study has also suggested that female experience the first stroke attack in older age than male. In 98 studies covering 19 countries and 5 continents, the average age of stroke that ever existed was 72.9 years in female compared with 68.6 years in male (Samai & Martin-Schild, 2015).

In addition to unmodifiable risk factors such as age and sex, there are also some modifiable risk factors such as smoking habits, hypertension, diabetes mellitus, heart disease, and previous history of stroke. From table 1 above, it can be concluded that hypertension is the most common risk factor in both groups (86.4%), with more male group (26 people) than female (12 people). According to statistical calculations with age variables, it turns out that hypertension has a stroke risk of 3 to 1 for male, and female 2.9 times more frequent than those with elderly with normal blood (Misbach, et al., 2011). A decrease of TDS to <130 mmHg also proved to reduce the incidence of recurrent stroke by 20% (Mozaffarian, et al., 2016). An increase in blood pressure may lead to endothelium dysfunction. This endothelium is a cell that covers the inside of a vein that has an important role in the regulation of vascular hemostasis. If endothelium dysfunction occurs, it will increase proinflammatory, prothrombotic, expression of adhesion molecules and cholesterol deposition. This can trigger the process of atherosclerosis and thus cause ischemic (Leopold, 2013).

In addition to hypertension, diabetes mellitus, heart disease, previous stroke history and smoking habits, influence the stroke inflammatory process. Smoking may increase the risk of ischemic stroke 2 times higher and 2 to 4 times higher in hemorrhagic stroke. 12% to 14% of total deaths in stroke have a relationship with smoking. Smoking affects the formation of thrombus in
Some of the therapies gained in patient rooms during the study (ASA, CDP Cholin, metamizole, vitamin B1, B6 and B12) may influence inflammatory cytokines as well. The antiplatelet Aspirin (ASA) effect irreversibly inhibits cyclooxygenase-1 thromboxy whole, which results in decreased platelet activation of thromboxane. ASA is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase pathways through arachidonic acid metabolism, which at high doses (1g) as anti-inflammatory, but at low doses of 75-150mg have cardioprotective and antiplatelet effects by inhibiting formation of thromboxanne (Tx) A2. Furthermore it is said that low-dose aspirin 75-150mg can reduce the innate immune response in humans by triggering 15-epi-lipoxin A4 of endothelial COX2 so it has anti-inflammatory properties (Morris, et al., 2009). Metamizole has an antiinflammatory effect by inhibiting cyclooxygenase enzymes thereby reducing prostaglandin synthesis (Cazacu, et al., 2015). CDP-Cholin can increase phosphatidylinosine levels by suppressing the stimulation of phospholipase A2 (PLA2) which is an inflammatory mediator (Adibhatla & Hatcher, 2005). The effect of vitamin B on inflammation is related to its effect on homocysteine. Increased levels of homocysteine are associated with low levels of vitamin B6 and vitamin B 12 in the blood. The condition of hyperhomocysteinemia increases oxidative stress and damage to vascular endothelial cells and reduces the production and bioavailability of nitric oxide (a strong relaxation factor) in the endothelium and triggers an inflammatory response (Folsom, et al., 2003; Hariri, et al., 2013).

Eventhough can influences inflammatory process, but there is no direct link between IL-6 and the above-mentioned drugs. To anticipate the existence of differences of risk factor characteristics in both groups, statistically different test is used, the result shows no significant difference between the two groups (p>0.05), so it can be accepted that the difference in the results of this study is not influenced by risk factors and the above-mentioned therapies.

In this study, it is found that serum IL-6 levels before intervention in both groups have mixed results. In Figure 1 and 2 it can be seen that serum levels of IL-6 control group before the intervention (pre) were 2.557 – 260.450 pg/ml, and after intervention (post) was 0 – 437.950 pg/ml. Meanwhile, the range of serum IL-6 levels in the treatment group before the intervention (pre) is 0 – 115.336 pg/ml and after intervention (post) is 0 – 53.937 pg/ml. The measurement of serum IL-6 levels before intervention was done to know the initial value of serum IL-6 in each patient. Several outcomes from previous studies suggest that serum IL-6 levels greatly vary among individuals so it is not possible to establish a definite serum IL-6 level and therefore the measurement of initial value of serum IL-6 levels is necessary as a common reference in acute ischemic stroke patients.

In table 2 above can be seen the difference in mean serum levels of IL-6 before and after intervention in the control and treatment group. The average of serum IL-6 levels before intervention in the control group is in the range 38,782 ± 74,216 pg/ml, it is higher than the treatment group with the range of 17,760 ± 25,253 pg/ml. The large standard deviation (SD) at the average serum IL-6 levels before and after this intervention reflects that the measured data has large variations. However, after the Mann-Whitney test it is found that the difference is not statistically significant with p>0.05 (p=0.438). Variations of serum IL-6 levels in each of these patients are a cause of the relation of serum IL-6 on the size of the lesions in the brain. Increased production of proinflammatory cytokines (TNF-α, interleukin (IL) - 1β, IL-6) correlates significantly with the vast of lesion size in animal models and worse clinical outcomes. The increase of this serum IL-6 levels is associated with worsening neurologic symptoms, increased infarct size and poor functional outcome (D0l14, et al., 2014). Cut point off IL-6 is 6.47 pg/ml (Shenhar-Tsarfaty, et al., 2010). In this study, serum IL-6 levels of 10 patients in the control group ml and of 13 patients in the treatment group are found greater than 6.47 pg/ml. Shenhar-Tsarfaty et al., states if IL-6 above 6.47 pg/ml during the acute phase predistest subsequent non-survival (p=0.006). In another study of Smith, et al., showed that peak plasma IL-6 concentration>30 pg/ml in the first week after an ischemic stroke were associated with increased mortality at 12 months. ). In this study, serum IL-6 levels of 3 patients in the control and the treatment groups are found greater than 30 pg/ml. However, in this study, the vast of infarct, NIHSS scores and outcome clinics of patients did not observed.

After the intervention, the average of serum IL-6 levels in the treatment group is in the range 15.928 ± 16.710 pg/ml lower than the control group with the range 46.586 ± 103.484 pg/ml. After the Mann-Whitney test it is found that the difference is not statistically significant with p>0.05 (p=0.589).
In comparison between before and after intervention in the same group, it is found that of 22 patients in the control group, serum IL-6 levels of 12 patients have increased (54.54%) while 9 patients have decreased (40.90%) and 1 of patients (4.54%) has no change in serum of IL-6 levels. The average of serum IL-6 levels before intervention increased from 38.594 pg/ml to 46.586 pg/ml after intervention. But, statistically, the increasing serum IL-6 levels do not show a significant difference (p=0.205). The decrease in serum IL-6 levels is due to the severity of the stroke can determine the survival time and the increase in serum IL-6 levels (DO114, et al., 2014). This study conducts no variations of length of study time, only on the first and fifth days, therefore a further study of longer or shorter duration is needed to add information on variation in serum IL-6 levels in acute ischemic stroke.

In the treatment group, there is 8 patients with decreasing serum IL-6 levels (36.36%), 12 patients with increased serum IL-6 level (54.54%) and 2 patients (2.09%) who have no change serum of IL-6 levels after consuming simvastatin for 5 days. In comparison between serum IL-6 levels before and after intervention, there is a depression from 17.760 pg/ml to 15.275 pg/ml, but this depression shows no significant significance (p=0.411). The increased serum IL-6 levels after consumption of simvastatin 20 mg on the fifth day may be due to drug interactions between phenytoin and simvastatin. Serum IL-6 levels of patient with code 22A increase from 11.448 pg/ml to 25.102 pg/ml. This patient has a history of 3x100mg phenytoin use due to post traumatic epilepsy and hospitalized in Seruni A. in the next overstay, the patient received Phenitoin 3x100 mg (iv) therapy because of the diagnosis of epilepsy. Simvastatin is metabolized by CYP3A4 isoenzyme, whereas phenytoin is a potent CYP3A4 isoenzyme inducer which can affect simvastatin metabolism. This causes simvastatin to be ineffective or decrease its effectiveness as the drug free level in the body decreases (Malloy M & Kane J, 2015; Suharjono, 2017).

This increase in serum IL-6 levels may also a result of heat shock proteins (Hsp70) activation in extracellular. In ischemic stroke conditions, besides causing passive release of Danger Associated Molecular Pattern Molecules (DAMPs), Hsp70 is also released. Hsp70 can interact with macrophages, microglia, and dendritic cells. Hsp70 forms ligands with Toll-like receptors (TLRs) 2 and 4 thereby causing activation transcription factor of Nuclear Factor Kappa B (NF-kB), which induces production of pro-inflammatory cytokines such as IL-6 (Kim & Yenari, 2013).

A Meta Analysis shows that the use of statins is associated with mild stroke severity, good functional outcomes and lower mortality (Hong & Lee, 2015). Tuttolomondo, et al, (2016) suggests the use of high-dose statins (atorvastatin ) 80 mg for 7 days in acute ischemic stroke patients, proving a decrease in serum TNF-α, IL-1β and IL-6 inflammatory markers (p<0.05). Similarly, a recent study shows that more aggressively statin therapy is associated with better long-term functional outcomes of the patients with acute ischemic stroke rather than less aggressive statin therapy (Fang, et al., 2017).

Various types of high-dose statins generally have anti-inflammatory effects. However, the use of high-dose statins should be considered as it may cause undesirable side effects. In this case, hydrophilic statins like rosuvastatin, less toxic when compared with lipophilic statins such as atorvastatin and simvastatin, due to first pass effect on the liver. In addition, although lipophilic statins easier to penetrate the blood-brain barrier, and potentially provide a protective effect on the nerves but the use of statins at high doses can cause toxic effects (Bonilla & Campos, 2012). During the study, the researcher found no side effects of simvastatin on study recipients such as, increased activity of serum transaminase to liver and muscle disorders (myalgia, myopathy, and rhabdomyolysis).

From the results of this study it can be concluded that giving simvastatin 20 mg for 5 days can decrease serum IL-6 level when compared with control group in acute ischemic stroke patient, although it is not statistically significant.

CONCLUSION

The use of simvastatin 20 mg may decrease serum IL-6 levels in acute ischemic stroke patients but statistically not significant.

ACKNOWLEDGMENT

The writers are grateful to the Director of Dr. Soetomo Hospital and Director of Universitas Airlangga Hospital, Surabaya, Head and staffs of SMF Science of Neurology Dr. Soetomo Hospital and Universitas Airlangga Hospital. The writers are also grateful to the Dean of the Faculty of Pharmacy, Universitas Airlangga, Head and staffs of the Clinical Pharmacy Master Program, Faculty of Pharmacy, Universitas Airlangga, Surabaya.
REFERENCES


